General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination

2014/01/06 by Aline Baldo, Eric den Akker, Hans Bergmans +2 · 2 citations
Biochemistry, Genetics and Molecular Biology · #Virus-based gene therapy research #Viral Infectious Diseases and Gene Expression in Insects #CRISPR and Genetic Engineering

paper · pdf · doi:10.2174/15665232113136660005

openalex publication_date 2014/01/06 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Abstract

This introductory paper gathers general considerations on the biosafety of virus-derived vectors that are used in human gene therapy and/or vaccination. The importance to assess the potential risks for human health and the environment related to the use of genetically modified organisms (GMO) in this case genetically modified viral vectors is highlighted by several examples. This environmental risk assessment is one of the requirements within the European regulatory framework covering the conduct of clinical trials using GMO. Risk assessment methodologies for the environmental risk assessment of genetically modified virus-derived vectors have been developed.

Cited by

• Viral Vectors in Gene Replacement Therapy
• Genetically modified organism [wikipedia]

Related

• Genetically Modified Microorganisms: Risks and Regulatory Considerations for Human and Environmental Health
• Evidence-Based Biosafety: a Review of the Principles and Effectiveness of Microbiological Containment Measures
• Viral Vectors in Gene Therapy
• Adequacy and sufficiency evaluation of existing EFSA guidelines for the molecular characterisation, environmental risk assessment and post‐market environmental monitoring of genetically modified insects containing engineered gene drives
• Vector-based genetically modified vaccines: Exploiting Jenner’s legacy